文献速递消化道肿瘤与早癌消化内镜

抗凝药与非甾体抗炎药对结直肠癌筛查中粪便免疫化学检测准确性影响的系统综述与荟萃分析

Effect of anticoagulants and NSAIDs on accuracy of faecal immunochemical tests (FITs) in colorectal cancer screening: a systematic review and meta-analysis.
PubMed 文献 · Gut · 2018-06-05

该系统综述与荟萃分析检索至2017年6月,纳入8项研究共3563例粪便免疫化学检测(FIT)阳性者,比较口服抗凝药(OACs)或阿司匹林/非甾体抗炎药(NSAIDs)使用者与非使用者FIT对进展期肿瘤的阳性预测值(PPVAN)。OACs使用者PPVAN为37.6%(95%CI 33.9-41.4),非使用者为40.3%(95%CI 38.5-42.1),p=0.75;阿司匹林/NSAIDs使用者PPVAN为38.2%(95%CI 33.8-42.9),非使用者为39.4%(95%CI 37.5-41.3),p=0.59。结论认为FIT准确性不受OACs及阿司匹林/NSAIDs使用影响,基于现有文献不推荐在FIT筛查前停用OACs或NSAIDs。

要点

  • OACs使用者FIT阳性后进展期肿瘤阳性预测值为37.6%(95%CI 33.9-41.4),非使用者为40.3%(95%CI 38.5-42.1),p=0.75。
  • 阿司匹林/NSAIDs使用者FIT阳性后进展期肿瘤阳性预测值为38.2%(95%CI 33.8-42.9),非使用者为39.4%(95%CI 37.5-41.3),p=0.59。
  • 基于现有文献,不推荐在FIT筛查前停用OACs或NSAIDs。

核心结论

  • FIT准确性不受OACs及阿司匹林/NSAIDs使用影响。
  • 基于现有文献,不推荐在FIT筛查前停用OACs或NSAIDs。
  • 未来研究应关注用药时长、剂量及药物类别与FIT准确性的关联,以制定更具体的指南推荐。

研究设计与样本

  • 系统检索PubMed、Embase、MEDLINE、Web of Science、Cochrane Central及Google Scholar,检索截至2017年6月。
  • 纳入报告平均风险结直肠癌筛查人群中OACs和/或NSAIDs使用者与非使用者FIT结果的研究。
  • 共检索到2022条记录,最终纳入8项研究,合计3563例FIT阳性参与者。
  • 主要结局为FIT对进展期肿瘤的阳性预测值(PPVAN)与OACs/NSAIDs使用的关系,采用随机效应森林图合并数值。

主要发现

  • OACs使用者FIT阳性后PPVAN为37.6%(95%CI 33.9-41.4),非使用者为40.3%(95%CI 38.5-42.1),p=0.75。
  • 阿司匹林/NSAIDs使用者FIT阳性后PPVAN为38.2%(95%CI 33.8-42.9),非使用者为39.4%(95%CI 37.5-41.3),p=0.59。

关键数值与推荐

  • OACs使用者PPVAN 37.6%(95%CI 33.9-41.4)对比非使用者40.3%(95%CI 38.5-42.1),p=0.75。
  • 阿司匹林/NSAIDs使用者PPVAN 38.2%(95%CI 33.8-42.9)对比非使用者39.4%(95%CI 37.5-41.3),p=0.59。

临床怎么用

  • 基于现有文献,不推荐在FIT筛查前停用OACs或NSAIDs。
  • 未来研究应关注用药时长、剂量及药物类别与FIT准确性的关联,以制定更具体的指南推荐。

局限性

  • 未来研究应关注用药时长、剂量及药物类别与FIT准确性的关联,以制定更具体的指南推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Most colorectal cancer (CRC) screening programmes are nowadays based on faecal immunochemical testing (FIT). Eligible subjects often use oral anticoagulants (OACs) or non-steroidal anti-inflammatory drugs (NSAIDs), which could possibly stimulate bleeding from both benign and premalignant lesions in the colon. The aim of this meta-analysis was to study the effect of OACs and NSAIDs use on FIT performance. DESIGN: A systematic search was conducted until June 2017 to retrieve studies from PubMed, Embase, MEDLINE, Web of science, Cochrane Central and Google Scholar. Studies were included when reporting on FIT results in users versus non-users of OACs and/or NSAIDs in average risk CRC screening populations. Primary outcome was positive predictive value for advanced neoplasia (PPVAN) of FIT in relation to OACs/NSAIDs use. Values were obtained by conducting random-effect forest plots. RESULTS: Our literature search identified 2022 records, of which 8 studies were included. A total of 3563 participants with a positive FIT were included. Use of OACs was associated with a PPVAN of 37.6% (95% CI 33.9 to 41.4) compared with 40.3% (95% CI 38.5 to 42.1) for non-users (p=0.75). Pooled PPVAN in aspirin/NSAID users was 38.2% (95% CI 33.8 to 42.9) compared with 39.4% (95% CI 37.5 to 41.3) for non-users (p=0.59). CONCLUSION: FIT accuracy is not affected by OACs and aspirin/NSAIDs use. Based on the current literature, withdrawal of OACs or NSAIDs before FIT screening is not recommended. Future studies should focus on duration of use, dosage and classes of drugs in association with accuracy of FIT to conduct more specific guideline recommendations.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Nieuwenburg SAV, Vuik FER, Kruip MJHA, et al. Effect of anticoagulants and NSAIDs on accuracy of faecal immunochemical tests (FITs) in colorectal cancer screening: a systematic review and meta-analysis. Gut. 2018. PMID: 29871970. doi:10.1136/gutjnl-2018-316344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。